Brenetafusp

Summary

Brenetafusp (CHEMBL5314729) is a phase-3 clinical-stage protein; indicated across 2 conditions including melanoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314729
Name	Brenetafusp
Type	Protein
Max phase	3

Also known as: Brenetafusp, IMC F106C, Imc-f106c, IMC-F106C, BRENETAFUSP

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	3	MONDO:0005105	EFO:0000756
neoplasm	2	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06112314	PHASE3	RECRUITING	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT04262466	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).